However, as also stated by study’s Authors, DPP4 inhibitors users were older and frailer than SGLT-2 inhibitors users before matching, thus suggesting that even after adjustment for many measured factors (such as frailty status and age) residual confounding factors may be present such as the presence of mild cognitive impairment (Zhuo et al., 2021). The gene discussed is SLC5A2; the disease is Cognitive impairment.